Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog

Cardiovascular Research

Volumn 27, Issue 5, 1993, Pages 832-838

  Yao, Zhenhai ^a   Auchampach, John A ^a   Pieper, Galen M ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Catalase; Endotoxin; Infarct size; Monophosphoryl lipid A; Myeloperoxidase activity; Myocardial ischaemia; Neutrophils

Indexed keywords

CATALASE; MYELOPEROXIDASE; PHOSPHORYL LIPID A;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMAL; CATALASE; COMPARATIVE STUDY; DISEASE MODELS, ANIMAL; DOGS; ENDOTOXINS; FEMALE; HEART; LIPID A; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEROXIDASE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 85047677864     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1093/cvr/27.5.832     Document Type: Article

References (38)

1. Morrison DC, Ryan JL. Bacterial endotoxins and host immune responses. Adv Immunol 1979;28:293–300.
2. Landy M, Pillemer L. Increased resistance to infection and accompanying alterations in properidin levels following administration of bacterial lipopolysaccharides. J Exp Med 1956;104:383–409.
3. Nowotny A, Butler RC. Studies on the endotoxin induced tumor resistance. Adv Exp Med Bio! 1980;121B:455–69.
4. Behling UH, Nowotny A. Immunostimulation by LPS and its derivatives. In: Friedman H, Klein TW, Szentivanyi A, eds. Immunomodulation by bacteria and their products. New York: Plenum Press, 1982:165–79.
5. Nowotny A. Endotoxoid preparations. Nature 1963, 197:721–2.
6. Johnson AG, Nowotny A. Relationship of structure to function in bacterial O antigens. III. Biological properties of endotoxins. J Bacteriol 1964;87:809–14.
7. Ribi E, Parker R, Strain SM, et al. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol Immunother 1979;7:43–58.
8. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from lipo-polysaccharide of Salmonella tvphimurium. J Biol Chem 1982;257:11808–15.
9. Takayama K, Qureshi N, Ribi E, Cantrell JL. Separation and characterization of toxic and nontoxic forms of lipid A’s. Rev Infect Dis 1984:6:439–43.
10. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Resp Modif 1984;3:1–9.
11. Brown JM, Grosso MA, Terada LS, et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 1989;86:2516–20.
12. Nelson DW, Brown JM, Banerjee A, et al Pretreatment with a nontoxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury. Surgery 1991;110:365–9.
13. Mullane KM, Read N, Salmon JA, Moncada S. Role for leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by antiinflammatory drugs. J Pharmacol Exp Ther 1984;228:510–22.
14. Farber NE, Vercellotti GM, Jacob HS, Pieper GM, Gross GJ. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in canine heart. Circ Res 1988;63:351–60.
15. Simpson PJ, Mickelson J, Fantone JC, Gallagher KP, Lucchesi BR. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in the canine heart. Circ Res 1987;60:666–73.
16. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985;14:157–67.
17. Schierwagen C, Bylund-Fellenius AC. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods 1990;23:179–86.
18. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121–6.
19. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971;133:885–900.
20. Jennings RB, Reimer KA. Factors involved in salvaging ischemic myocardium: Effect of reperfusion of arterial blood. Circulation 1984;68(suppl):I25–36.
21. Sommers HM, Jennings RB. Experimental acute myocardial infarction: histologic and histochemical studies of early myocardial infarcts induced by temporary or permanent occlusion of a coronary artery. Lab Invest 1964;13:1491–503.
22. Go LO, Murry CE, Richard VJ, Weischedel GR, Jennings RB, Reimer KA. Myocardial neutrophil accumulation during reperfusion and reversible and irreversible ischemic injury. Am J Phvsiol 1988;255:H 1188–98.
23. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;67:1016–23.
24. Jugdutt BI, Hutchin GM, Bulkley BH, Becker LC. Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog. Am J Cardiol 1980;46:74–82.
25. Simpson PJ, Mickelson J, Fantone JC, Gallagher KP, Lucchesi BR. Reduction of experimental canine myocardial infarct size with prostaglandin El: inhibition of neutrophil migration and activation. J Pharmacol Exp Ther 1988;244:619–24.
26. Lucchesi BR, Werns SW, Fantone JC. The role of the neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardiol 1989;21:1241–51.
27. Barroso-Aranda J, Schmid-Schonbein GW, Zweifach BW, Mathison JC. Polymorphonuclear neutrophil contribution to induced tolerance to bacterial lipopolysaccharide. Circ Res 1991;69:1196–206.
28. Van Dervort AL, Doerfler ME, Stuetz P, Danner RL. Antagonism of lipopolysaccharide-induced priming of human neutrophils by lipid A analogs. J Immunol 1992;149:359–66.
29. Bjorkman JA, Gustafsson SD, Sjoquist PO, Abrahamsson T. Superoxide dismutase and catalase do not improve recovery of regional myocardial contractile function when given at the time of reperfusion after reversible regional ischemia in anesthetized dogs. Basic Res Cardiol 1991:86:236–44.
30. Peterson DA, Asinger RW, Elsperger KJ, Homans DC, Eaton JW. Reactive oxygen species may cause myocardial reperfusion injury. Biochem Biophys Res Comm 1985;127:87–93.
31. Das DK, Engelman RM, Otani H, Rousou JA, Breyer RH, Lemeshow S. Effect of superoxide dismutase and catalase on myocardial energy metabolism during ischemia and reperfusion. Clin Physiol Biochem 1986;4:187–98.
32. Otani H, Umemoto M, Kagawa K, et al. Protection against oxygen-induced reperfusion injury of the isolated canine heart by superoxide dismutase and catalase. J Surg Res 1986;41:126–33.
33. Thayer WS. Role of catalase in metabolism of hydrogen peroxide by the perfuse rat heart. FEBS Lett 1986;202:137–40.
34. Currie RW, Karmazyn M, Kloc M, Mailer K. Heat-shock response is associated with enhanced postischemic ventricular recovery. Circ Res 1988;63:543–9.
35. Myers CL, Weiss SJ, Kirsh MM, Shlafer M. Involvement of hydrogen peroxide and hydroxyl radical in the ‘oxygen paradox’: reduction of creatine kinase release by catalase allopurinol or deferoxamine, but not by superoxide dismutase. J Mol Cell Cardiol 1985;17:675–84.
36. Perlmutter DH, Dinarello CA, Punsal PI, Colten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin invest 1986;78:1349–54.
37. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 1984;311:1413–8.
38. Brown JM, White CW, Terada LS, et al. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci USA 1990;87:5026–30.